Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade A 73.61 3.36% 2.39
SGEN closed up 3.36 percent on Friday, January 18, 2019, on 84 percent of normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Earnings due: Feb 5

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical SGEN trend table...

Date Alert Name Type % Chg
Jan 18 Wide Bands Range Expansion 0.00%
Jan 18 Overbought Stochastic Strength 0.00%
Jan 17 Slingshot Bullish Bullish Swing Setup 3.36%
Jan 17 Wide Bands Range Expansion 3.36%
Jan 17 Overbought Stochastic Strength 3.36%
Jan 16 Wide Bands Range Expansion 2.71%
Jan 16 Overbought Stochastic Strength 2.71%
Jan 15 Expansion Breakout Bullish Swing Setup 2.22%
Jan 15 Reversal New Highs Setup Bullish Swing Setup 2.22%
Jan 15 Multiple of Ten Bullish Other 2.22%

Older signals for SGEN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Is SGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 84.37
52 Week Low 47.75
Average Volume 1,036,517
200-Day Moving Average 64.8966
50-Day Moving Average 60.5034
20-Day Moving Average 62.968
10-Day Moving Average 70.079
Average True Range 2.8281
ADX 30.18
+DI 33.6342
-DI 12.3266
Chandelier Exit (Long, 3 ATRs ) 65.1557
Chandelier Exit (Short, 3 ATRs ) 59.9843
Upper Bollinger Band 78.0495
Lower Bollinger Band 47.8865
Percent B (%b) 0.85
BandWidth 47.902109
MACD Line 3.7187
MACD Signal Line 2.4787
MACD Histogram 1.24
Fundamentals Value
Market Cap 10.53 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -51.48
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 77.27
Resistance 3 (R3) 76.87 75.26 76.66
Resistance 2 (R2) 75.26 74.32 75.46 76.46
Resistance 1 (R1) 74.43 73.75 74.85 74.83 76.25
Pivot Point 72.82 72.82 73.02 73.02 72.82
Support 1 (S1) 71.99 71.88 72.41 72.39 70.97
Support 2 (S2) 70.38 71.31 70.58 70.76
Support 3 (S3) 69.55 70.38 70.56
Support 4 (S4) 69.95